4.7 Article

PAI-1-regulated miR-21 defines a novel age-associated fibrogenic pathway in muscular dystrophy

期刊

JOURNAL OF CELL BIOLOGY
卷 196, 期 1, 页码 163-175

出版社

ROCKEFELLER UNIV PRESS
DOI: 10.1083/jcb.201105013

关键词

-

资金

  1. Ministerio de Ciencia e Innovacion [PLE2009-0124, SAF2009-09782, FIS-PS09/01267]
  2. Centro de Investigacion Biomedica en Red
  3. Enfermedades Neurodegenerativas
  4. AFM
  5. Fundacio La Marato de TV3
  6. Muscular Dystrophy Association
  7. MYOAGE
  8. OptiStem
  9. EndoStem (EU)
  10. ICREA Funding Source: Custom

向作者/读者索取更多资源

Disruption of skeletal muscle homeostasis by substitution with fibrotic tissue constitutes the principal cause of death in Duchenne muscular dystrophy (DMD) patients, yet the implicated fibrogenic mechanisms remain poorly understood. This study identifies the extracellular PAI-1/urokinase-type plasminogen activator (uPA) balance as an important regulator of microribonucleic acid (miR)-21 biogenesis, controlling age-associated muscle fibrosis and dystrophy progression. Genetic loss of PAI-1 in mdx dystrophic mice anticipated muscle fibrosis through these sequential mechanisms: the alteration of collagen metabolism by uPA-mediated proteolytic processing of transforming growth factor (TGF)-beta in muscle fibroblasts and the activation of miR-21 expression, which inhibited phosphatase and tensin homologue and enhanced AKT signaling, thus endowing TGF-beta with a remarkable cell proliferation-promoting potential. Age-associated fibrogenesis and muscle deterioration in mdx mice, as well as exacerbated dystrophy in young PAI-1(-/-) mdx mice, could be reversed by miR-21 or uPA-selective interference, whereas forced miR-21 overexpression aggravated disease severity. The PAI-1-miR-21 fibrogenic axis also appeared dysregulated in muscle of DMD patients, providing a basis for effectively targeting fibrosis and muscular dystrophies in currently untreatable individuals.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据